Coltuximab Ravtansine

Coltuximab Ravtansine Uses, Dosage, Side Effects, Food Interaction and all others data.

Coltuximab Ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

Table Of contents

• Coltuximab Ravtansine
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Coltuximab Ravtansine
Generic	Coltuximab ravtansine
Coltuximab ravtansine Other Names	Anti-CD19 humanized monoclonal antibody conjugated to DM4, Coltuximab ravtansine
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in lymphoma (non-hodgkin's).

How Coltuximab Ravtansine works

SAR3419 is an anti-CD19-DM4 immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells. [National Cancer Institute Drug Dictionary]

Innovators Monograph

You find simplified version here Coltuximab Ravtansine